TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01864018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given PO
Study: NCT02299479

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom G4 Platinum CGM
Description: Blood glucose levels will be monitored using continuous glucose monitors (CGMs). Participants will be asked to verify CGM low blood sugars using their home glucometer. Insulin dose adjustments will be made if there is concern that nocturnal hypoglycemia is occurring in relation to high daytime activity.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activity monitor
Description: Participants will be asked to wear an activity monitor so that we may assess their daily activity level. Insulin dose adjustments will be made if there is concern that nocturnal hypoglycemia is occurring in relation to high daytime activity.
Study: NCT01132404

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprorelin
Description: Phase 2 portion of study: patients randomized to this arm will receive a subcutaneous injection of depot Leuprorelin in the abdomen once per month for up to 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-448
Description: Phase 1 portion of study:~Patients will be administered a single dose of depot formulation TAK-448 via subcutaneous abdominal injection and a single dose of placebo at a contralateral injection site~Phase 2 portion of the study:~Patients randomized to this arm will be administered depot formulation TAK-448 (up to 2 dose levels) via subcutaneous injection in the abdomen once per month for up to 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-448
Description: Phase 1 portion of study:~Patients will be administered a single dose of depot formulation TAK-448 via subcutaneous abdominal injection and a single dose of placebo at a contralateral injection site~Phase 2 portion of the study:~Patients randomized to this arm will be administered depot formulation TAK-448 (up to 2 dose levels) via subcutaneous injection in the abdomen once per month for up to 6 months
Study: NCT00543348

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CUTTING BALLOON ANGIOPLASTY
Description: CUTTING BALLOON

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: CUTTING BALLOON ANGIOPLASTY
Description: CUTTING BALLOON

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Balloon angioplasty
Description: HIGH PRESSURE BALLOON
Study: NCT00079118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Study: NCT02702505

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeoMTA
Description: A new formulation of MTA was developed in which bismuth oxide was omitted

Intervention type: OTHER
Group type: OTHER
Intervention: ProRoot MTA
Description: Control group
Study: NCT00696696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m\^2, intravenous, Days 1, 8, 15 for every 28-day cycle. In the absence of disease progression or toxicity, a patient may continue to receive gemcitabine, erlotinib, and sorafenib until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg, taken orally, once a day, Days 1-28 for every 28-day cycle. In the absence of disease progression or toxicity, a patient may continue to receive gemcitabine, erlotinib, and sorafenib until disease progression.
Study: NCT00613405

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stress + cue exposure
Description: Trier Social Stress Task(TSST): subject is asked to give a talk and perform a math task in front of an audience, follwed by neutral and marijuana cue exposure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No stress + cue exposure
Description: Neutral and marijuana-associated cue exposure (scripted imagery, in vivo cues).
Study: NCT01864018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib Citrate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01513603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLAG-M
Description: IV times 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLAG-M
Description: Chemotherapy
Study: NCT04315792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endoxifen
Description: Administration of Endoxifen for 3 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Administration of Placebo for 3 weeks
Study: NCT02388490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: Brentuximab vedotin administered by IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle. The dose of brentuximab vedotin is 1.8 mg/kg q 3 weeks.
Study: NCT01926080

Intervention type: OTHER
Group type: OTHER
Intervention: DVD Intervention Arm
Description: Half of the parents will be prospectively randomized to receive the educational bereavement DVD entitled 'Grieving in the NICU- Mending Broken Hearts When a Baby Dies Too Soon'. A specific aim of the study is to evaluate the additional benefit of the Bereavement DVD over standard bereavement care in reducing parents' grief by comparing level of grief at each time point between the intervention (DVD) and control (no DVD) group.
Study: NCT04231331

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ertugliflozin
Description: Ertugliflozin 5mg qd for 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo qd for 12 months
Study: NCT03087071

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02147093

Intervention type: DEVICE
Group type: OTHER
Intervention: Test (multi-focal)
Description: contact lens was to be worn a daily wear.

Intervention type: DEVICE
Group type: OTHER
Intervention: Test (multi-focal)
Description: contact lens was to be worn a daily wear.

Intervention type: DEVICE
Group type: OTHER
Intervention: Control (Sphere)
Description: contact lens was to be worn a daily wear with spectacles

Intervention type: DEVICE
Group type: OTHER
Intervention: Control (Sphere)
Description: contact lens was to be worn a daily wear with spectacles
Study: NCT04436016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine
Description: Ivabradine pills will be crushed and encapsulated for adequate dosing (0, 2.5mg, 5mg or 7.5 mg) and blinding.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Mannitol will be encapsulated for adequate blinding.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Mannitol will be encapsulated for adequate blinding.
Study: NCT03428633

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Paravertebral block using ropivacaine preoperatively and postoperatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Morphine intraoperatively and postoperatively
Study: NCT03759249

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep medical treatment
Description: The participant ungo Standard Sleep medical diagnostics. If a sleep disorder is diagnosed in the interventional Group the applicable therapy is conducted.~If the participant is randomized in the waiting Group the applicable Therapy is initiated after study completion.
Study: NCT00960206

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trident® Ceramic Insert/Trident® AD HA Acetabular Shell
Description: Trident® Ceramic Insert/Trident® AD HA Acetabular Shell

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alumina Insert/PSL® Microstructured Acetabular Shell or Secur-Fit® HA PSL® Acetabular Shell
Description: Alumina Insert/PSL® Microstructured Acetabular Shell or Secur-Fit® HA PSL® Acetabular Shell

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OmniFit® Series II Insert/OmniFit® PSL® Microstructured Acetabular Shell
Description: OmniFit® Series II Insert/OmniFit® PSL® Microstructured Acetabular Shell
Study: NCT03087071

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT04677400

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: More than Body Appearance (MBA) Intervention
Description: The MBA is an online psychological intervention designed to improve body image. The intervention lasts 15 days, and it comprises two types of activity (1st and 2nd week).~During the first week of the MBA intervention, participants sill read three blocks of psychoeducational material including information about: 1) body image; 2) positive body image and healthy lifestyles; and 3) body functionality.~During the second week participants produce 3 structured writing assessment pertaining to body functionality and why it is important. Each assignment focused on two areas of body functionality: 1) body's senses and physical capacities; 2) health and creative skills; 3) self-care/daily routine and communication with others. For each writing assignment, participants were asked to reflect, describe, and specify why these aspects of body functionality were personally important and meaningful to them.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: More than Body Appearance (MBA) Intervention
Description: The MBA is an online psychological intervention designed to improve body image. The intervention lasts 15 days, and it comprises two types of activity (1st and 2nd week).~During the first week of the MBA intervention, participants sill read three blocks of psychoeducational material including information about: 1) body image; 2) positive body image and healthy lifestyles; and 3) body functionality.~During the second week participants produce 3 structured writing assessment pertaining to body functionality and why it is important. Each assignment focused on two areas of body functionality: 1) body's senses and physical capacities; 2) health and creative skills; 3) self-care/daily routine and communication with others. For each writing assignment, participants were asked to reflect, describe, and specify why these aspects of body functionality were personally important and meaningful to them.
Study: NCT00696696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 400 mg, taken orally, twice a day, Days 1-28 for every 28-day cycle. In the absence of disease progression or toxicity, a patient may continue to receive gemcitabine, erlotinib, and sorafenib until disease progression.
Study: NCT03905512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEL-212
Description: Administered as specified in the treatment arm
Study: NCT02512237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARX788
Description: ARX788, an antibody drug conjugate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARX788
Description: ARX788, an antibody drug conjugate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARX788
Description: ARX788, an antibody drug conjugate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARX788
Description: ARX788, an antibody drug conjugate
Study: NCT01711970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study: NCT04687878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: 20 IU twice a day, intranasally, every day for 12 weeks
Study: NCT03905512

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KRYSTEXXA®
Description: Administered as specified in the treatment arm
Study: NCT00663819

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement
Description: Colorectal, coloanal, and ileoanal anastomotic staple line reinforcement with GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement configured for circular stapler

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Staple line without reinforcement
Description: colorectal and coloanal anastomotic staple line without reinforcement
Study: NCT04687878

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: twice a day, intranasally, every day for 12 weeks
Study: NCT00869349

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IFS
Description: The program will begin with a half day orientation to meet the trained professional coaches and other patients enrolled in the program. Following the orientation there will be group meetings of 8-10 RA patients every other week for twelve weeks with one of the trained coaches. In the weeks patients do not meet with the group, patients will have individual coaching sessions. The group meetings will last approximately 90 minutes and the individual meetings will last 50 minutes. A maintenance program will follow with bimonthly coaching sessions and a group meeting once a month over the next six months.~Three, six and nine months after the beginning of the program, patients will return to the hospital to complete the same research questionnaire and physical examination they received at baseline.
Study: NCT03580356

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ligelizumab
Description: Liquid in vial

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ligelizumab
Description: Liquid in vial
Study: NCT00869349

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: The intervention for the controls includes an initial meeting with a health professional. Once a month for 9 months, patients will received educational material and a follow-up phone call to ask if the patient received the information and to answer any questions about the material.
Study: NCT03580356

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab
Description: Lyophilized powder for solution in vial

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Liquid in vial
Study: NCT04450693

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TTAX01
Description: TTAX01 is a cryopreserved human umbilical cord product derived from donated human placental tissue following healthy, live, caesarian section, full-term births after determination of donor eligibility and placenta suitability. TTAX01 is manufactured by TissueTech Inc. utilizing a proprietary CRYOTEK® process, which devitalizes the living cells but retains the natural structural and biological characteristics relevant to this tissue. TTAX01 is aseptically processed in compliance with current Good Tissue Practices (cGTP). TTAX01 will be manufactured in various sizes, stored in a medium of lactated Ringer's/glycerol (1:1).

Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: Standard care is defined in this protocol to consist of the following:~* Debridement;~* Wound cleansing, using sterile saline, a non-ionic cleanser or a hypochlorous solution. Antiseptic agents including hydrogen peroxide, acetic acid, chlorhexidine, povidone/iodine, and cetrimide should not be used. Topical antimicrobials and silver dressings are also prohibited;~* Primary wound dressings including a non-adherent, standard foam pad with or without a hydrogel beneath the dressing, or and alginate dressing, as is appropriate to maintain a moist wound environment while managing exudate;~* A secondary retention bandage appropriate to the amount of wound exudate, so as to avoid maceration of the peri-wound skin;~* Off-loading device appropriate to the location of wound with full length boot or total contact cast (unless not appropriate where a substitute off-loading device can be made with sponsor approval); and,~* Appropriate use of systemic antibiotics.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: Standard care is defined in this protocol to consist of the following:~* Debridement;~* Wound cleansing, using sterile saline, a non-ionic cleanser or a hypochlorous solution. Antiseptic agents including hydrogen peroxide, acetic acid, chlorhexidine, povidone/iodine, and cetrimide should not be used. Topical antimicrobials and silver dressings are also prohibited;~* Primary wound dressings including a non-adherent, standard foam pad with or without a hydrogel beneath the dressing, or and alginate dressing, as is appropriate to maintain a moist wound environment while managing exudate;~* A secondary retention bandage appropriate to the amount of wound exudate, so as to avoid maceration of the peri-wound skin;~* Off-loading device appropriate to the location of wound with full length boot or total contact cast (unless not appropriate where a substitute off-loading device can be made with sponsor approval); and,~* Appropriate use of systemic antibiotics.
Study: NCT01279278

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Co-signed letter
Description: Patients receive a personalized letter co-signed by their general practitioner and the medical coordinator of ADECA.

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Classical Letter
Description: Patients receive classical letter signed by the coordinator doctor of ADECA
Study: NCT03387995

Intervention type: DEVICE
Intervention: LVIS stent
Description: The paitents treated by LVIS stent implantation.

Intervention type: DEVICE
Intervention: LVIS stent
Description: The paitents treated by LVIS stent implantation.

Intervention type: DEVICE
Intervention: LVIS stent
Description: The paitents treated by LVIS stent implantation.

Intervention type: DEVICE
Intervention: LVIS stent
Description: The paitents treated by LVIS stent implantation.

Intervention type: DEVICE
Intervention: LVIS stent
Description: The paitents treated by LVIS stent implantation.

Intervention type: DEVICE
Intervention: Solitaire stent
Description: The paitents treated by Solitaire stent implantation.

Intervention type: DEVICE
Intervention: Solitaire stent
Description: The paitents treated by Solitaire stent implantation.

Intervention type: DEVICE
Intervention: Solitaire stent
Description: The paitents treated by Solitaire stent implantation.

Intervention type: DEVICE
Intervention: Solitaire stent
Description: The paitents treated by Solitaire stent implantation.

Intervention type: DEVICE
Intervention: Solitaire stent
Description: The paitents treated by Solitaire stent implantation.

Intervention type: DEVICE
Intervention: Enterprise stent
Description: The paitents treated by Enterprise stent implantation.

Intervention type: DEVICE
Intervention: Enterprise stent
Description: The paitents treated by Enterprise stent implantation.

Intervention type: DEVICE
Intervention: Enterprise stent
Description: The paitents treated by Enterprise stent implantation.

Intervention type: DEVICE
Intervention: Enterprise stent
Description: The paitents treated by Enterprise stent implantation.
Study: NCT01785732

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Renal Denervation
Description: Sympathetic renal denervation via renal arteries
Study: NCT01899690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antibiotic
Description: Patients after breast reconstruction with implant/tissue expander reconstruction who receive the intervention will be prescribed with a 7 day course of postoperative antibiotics.
Study: NCT02442362

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel+oxaliplatin+fluorouracil
Description: Patients treated with paclitaxel+oxaliplatin+fluorouracil: paclitaxel (135 mg/m2 iv) on day 1, oxaliplatin (100 mg/m2 iv) on day 1, fluorouracil (500 mg/m2 continuous iv) on day 1-5twice/day for body surface area between 1.25 and 1.50 m2 orally) on days 1-14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin+S1
Description: Patients treated with oxaliplatin+S1: oxaliplatin (130 mg/m2 iv) on day 1 and S-1 (40 mg twice/day for body surface area \< 1.25 m2 and 60 mg twice/day for body surface area between 1.25 and 1.50 m2 orally) on days 1-14
Study: NCT01541124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioid
Description: 10 mg/pill, po, each 6h, during 6m
Study: NCT03258489

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous nervous electric stimulation (TENS)
Description: TENS (Frequency 10 Hz or 100Hz /duration 200μs, Endophasys nms 0501® model, KLD Biosystems, Amparo, SP, Brazil) will be applied with intensity between 1 to 60 mA and the current will be adjusted every 5 minutes at the sensory threshold level muscle contraction or according to the tolerance to the stimulus informed by the volunteers. TENS will be applied in bilateral paravertebral region of C7 to T4 or long the brachial plexus and sciatic plexus.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Interferential electrical stimulation (IES)
Description: The IES (Endophasys nms 0501®, KLD Biosystems, Amparo, SP, Brazil) will be applied in continuous mode with biphasic pulses. Bipolar electrodes with slope of 1/5/1. The rest of the parameters will be set to 4000 Hz, AMF of 100 Hz and the AMF variation of 25 Hz. The effect of the current will be adjusted by the intensity, it should produce paresthesia stimuli, without pain and below the motor threshold. Adhesive electrodes (MultiStick®, Axelgaard Manufacturing CO, Ltd, Fallbrook, CA, USA) will be housed in the paravertebral region, between C7 (Channel 1) and T4 (Channel 2). (SANTOS et al., 2013)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: TENS and IES Placebo
Description: Same protocol without electrical output.
Study: NCT02562794

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Strengthening Intervention-Refugees
Description: This study aims to design a preventive intervention for at-risk refugee children and families. The intervention is focused on strengthening core family resources and promoting resilience and healthy parent-child interactions.
Study: NCT00891254

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implant of a prosthetic mesh
Description: A prosthetic mesh will be implanted either intraperitoneally or in the on-lay (supra-fascial) position depending on the arm of the study

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implant of a prosthetic mesh
Description: A prosthetic mesh will be implanted either intraperitoneally or in the on-lay (supra-fascial) position depending on the arm of the study
Study: NCT04563793

Intervention type: DEVICE
Intervention: Superion™ IDS
Description: All patients to receive IDS for the treatment of moderate Lumbar Spinal Stenosis symptoms.